Credits Available: 4.75 AMA PRA Category 1 Credit™/ MOC Points

Description: This curriculum examines the latest advancements in antibody-drug conjugate (ADC) therapy for metastatic triple-negative breast cancer (mTNBC) and HER2-low (HER+/HER2-) breast cancer. It provides insights into mechanisms of action, emerging clinical data, and strategies for integrating ADCs into treatment regimens to improve patient outcomes. Expert-led discussions and case-based learning will support clinicians in individualizing therapy and addressing real-world challenges in ADC use.

CME/CE Accreditation Information

If you already have a Gather-ed account, please login

Email:
Password:

Register

Step 1 of 3

This program is intended for:
Target Professions: DO, MD, Nurse Practitioner, Physician Associate/Assistant
Target Specialties: Oncology

Elizabeth Sakach

Winship Cancer Institute of Emory University
Assistant Professor, Breast Medical Oncology

Elizabeth Sakach is an assistant professor and breast medical oncologist at Winship Cancer Institute of Emory University. Dr. Sakach earned her medical degree from Texas A&M College of Medicine in College Station, Texas. She completed her residency in internal medicine and fellowship in hematology and medical oncology at Emory University School of Medicine in Atlanta, Georgia, where she served as chief fellow. She completed an additional fellowship in cancer drug development with the FDA-AACR. Dr. Sakach's research is focused on mechanisms of resistance and novel therapeutics for patients with advanced breast cancer. She is an active member of the phase I clinical trials unit at the Winship Cancer Center.